Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 105, Issue 2, Pages 246-254
Publisher
Springer Nature
Online
2011-06-29
DOI
10.1038/bjc.2011.197
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PIK3CA Mutation in Colorectal Cancer: Relationship with Genetic and Epigenetic Alterations
- (2015) Katsuhiko Nosho et al. NEOPLASIA
- Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicine
- (2010) G Smith et al. BRITISH JOURNAL OF CANCER
- Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
- (2010) S. E. Baldus et al. CLINICAL CANCER RESEARCH
- Bevacizumab: current updates in treatment
- (2010) Margaret EM Van Meter et al. CURRENT OPINION IN ONCOLOGY
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
- (2010) Wendy De Roock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues
- (2009) Sandrine Dufort et al. ANALYTICAL BIOCHEMISTRY
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
- (2009) A. Sartore-Bianchi et al. CANCER RESEARCH
- PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer
- (2009) H. Prenen et al. CLINICAL CANCER RESEARCH
- Chemotherapy, which drugs and when
- (2009) Miriam Koopman et al. EUROPEAN JOURNAL OF CANCER
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
- (2009) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer
- (2009) Cathy Eng Nature Reviews Clinical Oncology
- High-Resolution Melting Analysis for Rapid Detection ofKRAS, BRAF,andPIK3CAGene Mutations in Colorectal Cancer
- (2008) Lisa Simi et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- EGFR and colon cancer: a clinical view
- (2008) Javier de Castro-Carpeño et al. Clinical & Translational Oncology
- Epigenetic-Genetic Interactions in the APC/WNT, RAS/RAF, and P53 Pathways in Colorectal Carcinoma
- (2008) Y. Suehiro et al. CLINICAL CANCER RESEARCH
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
- (2008) Astrid Lièvre et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- (2008) Carsten Bokemeyer et al. JOURNAL OF CLINICAL ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Setting future standards for KRAS testing in colorectal cancer
- (2008) Han van Krieken et al. PHARMACOGENOMICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started